Modern molecular targeted therapies have shown promise in treating some blood cancers, but a cure remains elusive for most acute leukemia patients. This is largely due to the survival of some leukemic cells that possess unique properties and can cause treatment failure or relapse, warranting identification of new, distinct targets for improved therapies. In collaboration […]

Alzheimer’s disease (AD) is the most common neurodegenerative disorder. SignalChem LifeSciences Corp. recently developed a potent small molecule inhibitor (SLC-0149) for targeting CAIX, a hypoxia inducible gene, in the application of treating cancers. Since hypoxia has been implicated as a factor to facilitate AD development, this study aims to explore the potentiality of applying SLC-0149 […]

Modern molecular targeted therapies have shown promise in treating some blood cancers, but a cure remains elusive for most acute leukemia patients. This is largely due to the survival of some leukemic cells that possess unique properties and can cause treatment failure or relapse, warranting identification of new, distinct targets for improved therapies. In collaboration […]

Blood cancer (leukemia) is common, with ~48,600 and 6,400 new cases expected in the United States and Canada respectively in 2016. The National Cancer Institute (US) calculated an overall 5-year survival rate of 56% for various blood cancers. This is because most current therapies are short-lived; drug resistance and relapse pose significant clinical problems. Life-long […]